Previous Close | 32.48 |
Open | 0.00 |
Bid | 32.47 x 2000 |
Ask | 32.49 x 6600 |
Day's Range | 32.48 - 32.48 |
52 Week Range | 7.26 - 32.50 |
Volume | |
Avg. Volume | 3,971,638 |
Market Cap | 3.728B |
Beta (5Y Monthly) | 0.32 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.99 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 32.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for CBAY
FOSTER CITY, Calif., March 22, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio and aligns with its long-standing commitment to br
For us, stock picking is in large part the hunt for the truly magnificent stocks. You won't get it right every time...
MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. FDANEWARK, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the Marketing Authorization Application (MAA) for seladelpar, for the treatment of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated ci